IMNN Imunon Inc: Net earnings per share growth forecast for next year
Historically, Imunon, Inc. (IMNN) quotes relied on phase II ovarian cancer therapy trials. The projection of the company's EPS for the next year captures the current trend, where 24.70 becomes the new value of the indicator. In the future, the success of the DNA platform will ensure low cost of sales during scaling, although financial stability currently depends entirely on regulatory approval and the absence of stable revenue.
IMNN (Celsion Corporation): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- company stock capitalization data:
- company book value details:
- debt obligations and liquidity statistics:
- earnings and valuation multiples information:
IMNN - Company Profit|Expected Profit Imunon, Inc.|IMNN - Price to Earnings Multiple|Forward P/E Multiple Celsion Corporation|IMNN - PEG Multiple|EV/EBITDA Multiple IMNN|IMNN - Operating income before deduction of amortization|Earnings per share for the last twelve months Imunon|IMNN - Net earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months imunon.com|IMNN - Earnings growth in current year|Net earnings per share growth forecast for next year Imunon, Inc.
- sales volume and revenue indicators:
Comprehensive company analysis:IMNN, Celsion Corporation
This indicator reflects the analysts' consensus forecast for earnings changes in the coming period relative to current values. The calculation mechanics are based on the difference between expected and actual EPS, where the current 24.70 level signals market yield expectations. By analyzing the projected EPS dynamics for the coming year, an investor can see the impact of FDA regulatory risks and the expansion rate of the patient base for IMNN-001 therapy on the capitalization of Imunon, Inc. (IMNN).
Competing companies
TEM (Tempus) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year QGEN (Qiagen)|Earnings growth forecast for next year IONS|RGEN (Repligen) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year aviditybiosciences.com RNA|CRISPR (CRSP) - Expected net earnings per share growth next year|genedx.com - Earnings growth forecast for next year|Expected earnings per share trend next year RARE (ultragenyx.com)|BEAM: Earnings growth forecast for next year|Sarepta - Expected earnings per share trend next year|TWST (twistbioscience.com) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year TXG (10x Genomics Corp)|Earnings growth forecast for next year NTLA|Earnings growth forecast for next year Stoke Therapeutics, Inc. (STOK)|Net earnings per share growth forecast for next year BioLife BLFS|WVE - Expected earnings per share growth for next year|Maze Therapeutics Corp - Earnings growth forecast for next year|Sionna Pharma - Projected earnings per share increase next year|Prime Medicine (PRME) - Net earnings per share growth forecast for next year|tayshagtx.com (TSHA) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year uniQure Corp|MGTX: Expected earnings per share trend next year|Earnings growth forecast for next year RGNX|Consensus forecast of earnings per share growth for next year Solid Corp|Earnings growth forecast for next year OCGN (ocugen.com)|PACB (Pacific Biosciences) - Net earnings per share change forecast for next year|Benitec Biopharma Inc - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year Design Therapeutics, Inc. DSGN|Rocket Corp (RCKT) - Net earnings per share growth forecast for next year|4D Molecular Therapeutics (FDMT) - Earnings growth forecast for next year|LXEO (Lexeo Therapeutics, Inc.) - Earnings growth forecast for next year|Expected net earnings per share growth next year korrobio.com KRRO|Expected earnings per share growth for next year EDIT (Editas Medicine, Inc.)|Silence Therapeutics plc - Projected earnings per share growth rate for next year|Net earnings per share growth forecast for next year ProQR Therapeutics N.V. PRQR|Consensus forecast of earnings per share growth for next year Codexis, Inc. (CDXS)|SGMO - Net earnings per share growth forecast for next year|nautilus.bio - Projected earnings per share increase next year|Metagenomi, Inc (MGX) - Net earnings per share growth forecast for next year|Projected earnings per share growth rate for next year DTIL|Net earnings per share growth forecast for next year Generation Bio|Earnings growth forecast for next year Boundless Bio Inc|Net earnings per share growth forecast for next year Exicure Corp (XCUR)|PHIO (Phio Pharmaceuticals Corp.) - Expected earnings per share trend next year|Earnings growth forecast for next year MBIO (Mustang Bio Corp)|Projected earnings per share increase next year RNAZ (TransCode Therapeutics)|BNGO - Net earnings per share growth forecast for next year|APDN: Net earnings per share growth forecast for next year|BLUE: Earnings growth forecast for next year|Expected earnings per share growth for next year ImmunoPrecise Antibodies|OMGA (Omega Therapeutics, Inc.) - Earnings growth forecast for next year|Singular Genomics (OMIC) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Regulus (RGLS)|SYRS (Syros Pharmaceuticals, Inc) - Expected earnings per share trend next year|Telesis Bio, Inc. - Expected earnings per share growth for next year|TCON: Projected earnings per share growth rate for next year|Unity Biotechnology Inc. - Earnings growth forecast for next year
